Loracarbef is a synthetic "carba" analog of cefaclor, and is more stable.

Loracarbef received FDA approval in 1991 and it was marketed under the trade name Lorabid.

[citation needed] Loracarbef was used to treat infections of the lungs, maxillary sinuses, throat, skin, and urinary tract.

[2] Loracarbef had broad spectrum effectiveness against both gram-negative and gram-positive bacteria, including those precipitating infections of the respiratory tract, sinuses, tonsils, skin, urinary tract, and kidneys.

Side effects are more frequently seen with children under the age of twelve.